The primary objective is to observe the rate of recovery of ventricular function (EF\>35%) after first-time coronary artery bypass graft surgery in patients who were prescribed the wearable cardioverter defibrillator (WCD) post-surgery prior to being discharged after hospitalization as part of standard clinical care.
The primary objective of this study is to determine the rate of recovery of ventricular function (EF\>35%) in patients with ischemic heart failure with reduced ejection fraction (EF ≤35%) after undergoing first time, coronary artery bypass grafting (CABG) procedure while being treated with guideline-directed medical therapy (GDMT). It is anticipated that more patients will have EF recovery as compared to a retrospective register where 54% of isolated CABG patients had EF recovery by end of WCD use (Kuehn et al., 2022), mostly driven by the modern improved usage of GDMT drugs. This study is designed as a multi-center prospective observational study of patients who underwent first time coronary artery bypass grafting procedure with HFrEF at hospital discharge to test the hypothesis that EF recovery will be improved by end of WCD wear due to increased usage of GDMT. The study will target 20% female enrollment and recruitment will be adjusted if the percentage of female subjects enrolled are far from 20%.
Study Type
OBSERVATIONAL
Enrollment
910
An FDA-approved, CE marked WCD will be prescribed for up to 3 months of use after hospital discharge, with the option for longer use under physician discretion
Kerckhoff Klinik
Bad Nauheim, Hesse, Germany
NOT_YET_RECRUITINGMedizinische Hochschule Hannover
Hanover, Lower Saxony, Germany
RECRUITINGSana-Herzzentrum Cottbus GmbH
Cottbus, Germany
RECRUITINGEF recovery
EF recovery at end of WCD use, usually after 90days of wear. End of WCD use will be determined by the prescribing physician. For this study, EF\>35% will be considered as EF recovery.
Time frame: Enrollment till WCD End of Use
Quality of Life (KCCQ
Quality of Life (QoL) information will be collected using the following questionnaires: \- Kansas City Cardiomyopathy Questionnaire short form (KCCQ-12)
Time frame: Enrollment till WCD End of Use, usually up to three month
Quality of Life EQ
Quality of Life (QoL) information will be collected using the following questionnaires: \- EQ-5D-5L
Time frame: Enrollment till WCD End of Use, usually up to three month
Medication Adherence
Medications and self-reported adherence to taking those medications as prescribed will be recorded from chart review and patient interview, if necessary, every month (30 days). Medications will also be recorded at the start and end of WCD use
Time frame: Enrollment till WCD End of Use, usually up to three month
Healthcare utilization
Information (days, reasons) on any hospitalizations, emergency room visits, observation stays, urgent care visits, other physician office visits, and stays at skilled nursing facilities.
Time frame: Enrollment till WCD End of Use, usually up to three month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Universitätsklinikum Halle (Saale)
Halle, Germany
RECRUITING